March 2025 in “World Journal of Stem Cells” This study found that human adipose-derived MSC exosomes (hADSC-Exos) may enhance dermal papillary cell proliferation and migration by activating the Wnt/β-catenin signaling pathway, potentially reversing the effects of dihydrotestosterone in androgenetic alopecia.
November 2024 in “Journal of Cosmetic Dermatology” In this case series, mesenchymal stem cell exosomes were reported to improve hair length, density, pigmentation, and cuticle layer recovery in three patients with acquired trichorrhexis nodosa, suggesting potential as a therapeutic approach for this hair condition.
1 citations
,
December 2025 in “Stem Cell Research & Therapy” This study found that hucMSC-EXOs delivered via intratympanic injection effectively target vestibular sensory tissues, significantly reducing gentamicin-induced balance issues and high-frequency hearing loss, with some measured outcomes surpassing those achieved with dexamethasone.
April 2026 in “Frontiers in Cell and Developmental Biology” This study found that exosomes from human umbilical cord mesenchymal stem cells reduced hair follicle aging and promoted hair regeneration in models by upregulating COL17A1 through the miR-21-5p/DKK2/Wnt/β-catenin axis, outperforming existing treatments like minoxidil.
April 2026 in “Biosaintifika Journal of Biology & Biology Education” This study found that in a fluconazole-induced alopecia-like rat model, a 14-day treatment with hypoxia-induced mesenchymal stem cell exosomes significantly increased TGF-β and PDGF levels, which may improve hair growth and suggests a potential therapeutic strategy for alopecia and other inflammation-related skin disorders.